CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS
Publication
, Conference
Lancet, J; Uy, G; Cortes, J; Newell, L; Lin, T; Ritchie, E; Strickland, S; Stuart, R; Hogge, D; Solomon, S; Stone, R; Bixby, D; Kolitz, J ...
Published in: HAEMATOLOGICA
June 1, 2016
Duke Scholars
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 1, 2016
Volume
101
Start / End Page
186 / 186
Location
Copenhagen, DENMARK
Publisher
FERRATA STORTI FOUNDATION
Conference Name
21st Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Lancet, J., Uy, G., Cortes, J., Newell, L., Lin, T., Ritchie, E., … Medeiros, B. (2016). CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS. In HAEMATOLOGICA (Vol. 101, pp. 186–186). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
Lancet, J., G. Uy, J. Cortes, L. Newell, T. Lin, E. Ritchie, S. Strickland, et al. “CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS.” In HAEMATOLOGICA, 101:186–186. FERRATA STORTI FOUNDATION, 2016.
Lancet J, Uy G, Cortes J, Newell L, Lin T, Ritchie E, et al. CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 186–186.
Lancet, J., et al. “CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS.” HAEMATOLOGICA, vol. 101, FERRATA STORTI FOUNDATION, 2016, pp. 186–186.
Lancet J, Uy G, Cortes J, Newell L, Lin T, Ritchie E, Strickland S, Stuart R, Hogge D, Solomon S, Stone R, Bixby D, Kolitz J, Schiller G, Wieduwilt M, Rao A, Rubenstein S, Stock W, Foster M, Erba H, Goldberg S, Powell B, Podoltsev N, Atallah E, Warlick E, Yee K, Pagel J, Norkin M, Barta S, Sandhu I, Frankfurt O, Gautier M, Larson M, Seiter K, Levy M, Bergeron J, Berdeja J, Kropf P, Shemanski L, Ryan D, Chiarella M, Paulsen K, Louie A, Medeiros B. CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 186–186.
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 1, 2016
Volume
101
Start / End Page
186 / 186
Location
Copenhagen, DENMARK
Publisher
FERRATA STORTI FOUNDATION
Conference Name
21st Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology